Home
BCDA
BCDA News

Latest BioCardia Inc. (BCDA) News on October 16, 2025

BioCardia Regains Compliance with Nasdaq Listing Requirements

GlobeNewswire

14 days ago

BioCardia Regains Compliance with Nasdaq Listing Requirements

BioCardia Announces Positive Preliminary Clinical Consultation with Japan Pharmaceutical and Medical Device Agency on Cell Therapy for Ischemic Heart Failure

GlobeNewswire

24 days ago

BioCardia Announces Positive Preliminary Clinical Consultation with Japan Pharmaceutical and Medical Device Agency on Cell Therapy for Ischemic Heart Failure

Bullish BioCardia Insider Buying Worth US$1.06m Yet To Pay Off

Simply Wall St.

25 days ago

Bullish BioCardia Insider Buying Worth US$1.06m Yet To Pay Off

BioCardia Announces New United States Patent for Helix Biotherapeutic Delivery System

GlobeNewswire

4 months ago

BioCardia Announces New United States Patent for Helix Biotherapeutic Delivery System

Argus Research

4 months ago

Daily – Vickers Top Insider Picks for 06/04/2025

Argus Research

4 months ago

Daily – Vickers Top Insider Picks for 06/03/2025

Argus Research

4 months ago

Daily – Vickers Top Insider Picks for 06/02/2025

Argus Research

5 months ago

Daily – Vickers Top Insider Picks for 05/30/2025

Argus Research

5 months ago

Daily – Vickers Top Insider Picks for 05/29/2025

Argus Research

5 months ago

Daily – Vickers Top Insider Picks for 05/28/2025

Argus Research

5 months ago

Daily – Vickers Top Insider Picks for 05/27/2025

Argus Research

5 months ago

Daily – Vickers Top Insider Picks for 05/23/2025

Argus Research

5 months ago

Daily – Vickers Top Insider Picks for 05/22/2025

BioCardia to Participate in Fireside Chat at A.G.P. Virtual Healthcare Company Showcase on May 21, 2025

GlobeNewswire

5 months ago

BioCardia to Participate in Fireside Chat at A.G.P. Virtual Healthcare Company Showcase on May 21, 2025

Argus Research

5 months ago

Daily – Vickers Top Insider Picks for 05/21/2025

Argus Research

5 months ago

Daily – Vickers Top Insider Picks for 05/20/2025

Argus Research

5 months ago

Daily – Vickers Top Insider Picks for 05/16/2025

Argus Research

5 months ago

Daily – Vickers Top Insider Picks for 05/15/2025

BioCardia Inc (BCDA) Q1 2025 Earnings Call Highlights: Progress in Cardiac Cell Therapy Amid ...

GuruFocus.com

5 months ago

BioCardia Inc (BCDA) Q1 2025 Earnings Call Highlights: Progress in Cardiac Cell Therapy Amid ...

BioCardia Reports First Quarter 2025 Business Highlights and Financial Results

GlobeNewswire

5 months ago

BioCardia Reports First Quarter 2025 Business Highlights and Financial Results

Argus Research

5 months ago

Daily – Vickers Top Insider Picks for 05/14/2025

Argus Research

5 months ago

Daily – Vickers Top Insider Picks for 05/13/2025

BioCardia to Host Q1 2025 Corporate Update and Financial Results Conference Call on May 14, 2025

GlobeNewswire

5 months ago

BioCardia to Host Q1 2025 Corporate Update and Financial Results Conference Call on May 14, 2025

Argus Research

5 months ago

Daily – Vickers Top Insider Picks for 05/09/2025

Argus Research

5 months ago

Daily – Vickers Top Insider Picks for 05/08/2025

Argus Research

5 months ago

Daily – Vickers Top Insider Picks for 05/07/2025

BioCardia Initiates Patient Enrollment at University of Wisconsin at Madison for Ongoing CardiAMP HF II Pivotal Study

GlobeNewswire

5 months ago

BioCardia Initiates Patient Enrollment at University of Wisconsin at Madison for Ongoing CardiAMP HF II Pivotal Study

Argus Research

5 months ago

Daily – Vickers Top Insider Picks for 05/06/2025

Argus Research

5 months ago

Daily – Vickers Top Insider Picks for 05/05/2025

First subject enrolled in BioCardia’s Phase III heart failure therapy trial

Clinical Trials Arena

5 months ago

First subject enrolled in BioCardia’s Phase III heart failure therapy trial

Argus Research

5 months ago

Daily – Vickers Top Insider Picks for 05/02/2025

Biotech Alert: Searches spiking for these stocks today

TipRanks

5 months ago

Biotech Alert: Searches spiking for these stocks today

BioCardia Announces First Patient in Phase 3 Randomized Controlled Double-Blind CardiAMP HF II Clinical Trial of the Company’s Lead Cell Therapy for Treatment of Heart Failure

GlobeNewswire

5 months ago

BioCardia Announces First Patient in Phase 3 Randomized Controlled Double-Blind CardiAMP HF II Clinical Trial of the Company’s Lead Cell Therapy for Treatment of Heart Failure

Argus Research

5 months ago

Daily – Vickers Top Insider Picks for 05/01/2025

Argus Research

6 months ago

Daily – Vickers Top Insider Picks for 04/30/2025

Argus Research

6 months ago

Daily – Vickers Top Insider Picks for 04/29/2025

Argus Research

6 months ago

Daily – Vickers Top Insider Picks for 04/28/2025

Argus Research

6 months ago

Daily – Vickers Top Insider Picks for 04/25/2025

Argus Research

6 months ago

Daily – Vickers Top Insider Picks for 04/24/2025

Argus Research

6 months ago

Daily – Vickers Top Insider Picks for 04/23/2025

Argus Research

6 months ago

Daily – Vickers Top Insider Picks for 04/22/2025

Argus Research

6 months ago

Daily – Vickers Top Insider Picks for 04/21/2025

Argus Research

6 months ago

Daily – Vickers Top Insider Picks for 04/18/2025

Argus Research

6 months ago

Daily – Vickers Top Insider Picks for 04/17/2025

Argus Research

6 months ago

Daily – Vickers Top Insider Picks for 04/16/2025

DSMB recommends continuation of BioCardia’s cell therapy trial for heart failure

Clinical Trials Arena

6 months ago

DSMB recommends continuation of BioCardia’s cell therapy trial for heart failure

BioCardia Announces Positive DSMB Review of CardiALLO Allogeneic Cell Therapy for Heart Failure Phase 1/2 Clinical Trial

GlobeNewswire

6 months ago

BioCardia Announces Positive DSMB Review of CardiALLO Allogeneic Cell Therapy for Heart Failure Phase 1/2 Clinical Trial

Argus Research

6 months ago

Daily – Vickers Top Insider Picks for 04/15/2025

Emory begins enrolment for BioCardia’s trial of ischemic heart failure therapy

Clinical Trials Arena

6 months ago

Emory begins enrolment for BioCardia’s trial of ischemic heart failure therapy

Argus Research

6 months ago

Daily – Vickers Top Insider Picks for 04/14/2025

MT Newswires

6 months ago

BioCardia Says Emory University Enrolling Heart Patients for CardiAMP HF II Trial

BioCardia Initiates Patient Enrollment at Emory University School of Medicine for Ongoing CardiAMP HF II Pivotal Study

GlobeNewswire

6 months ago

BioCardia Initiates Patient Enrollment at Emory University School of Medicine for Ongoing CardiAMP HF II Pivotal Study

Argus Research

6 months ago

Daily – Vickers Top Insider Picks for 04/11/2025

Argus Research

6 months ago

Daily – Vickers Top Insider Picks for 04/10/2025

Argus Research

6 months ago

Daily – Vickers Top Insider Picks for 04/09/2025

Argus Research

6 months ago

Daily – Vickers Top Insider Picks for 04/08/2025

Argus Research

6 months ago

Daily – Vickers Top Insider Picks for 04/07/2025

Argus Research

6 months ago

Daily – Vickers Top Insider Picks for 04/04/2025

Thomson Reuters StreetEvents

6 months ago

Q4 2024 BioCardia Inc Earnings Call

BioCardia Inc (BCDA) Q4 2024 Earnings Call Highlights: Strategic Cost Reductions and Promising ...

GuruFocus.com

6 months ago

BioCardia Inc (BCDA) Q4 2024 Earnings Call Highlights: Strategic Cost Reductions and Promising ...

ACC 25: Biocardia’s CardiAMP trial fails but cell therapy potential remains

Clinical Trials Arena

6 months ago

ACC 25: Biocardia’s CardiAMP trial fails but cell therapy potential remains

BioCardia’s Conference Call Today, Monday, March 31, 2025 to be Held at 4:30PM EDT Time Today

GlobeNewswire

6 months ago

BioCardia’s Conference Call Today, Monday, March 31, 2025 to be Held at 4:30PM EDT Time Today

MT Newswires

6 months ago

BioCardia's Ischemic HF Cell Therapy Trial Reached no 'Statistical Significance' in Primary Composite Efficacy Endpoint

Biocardia Phase 3 CardiAMP-HF Trial of Novel Cardiac Cell Therapy for Ischemic Heart Failure Shows Increased Survival, Decreased Cardiac Events, and Improved Quality of Life at Two Years

GlobeNewswire

7 months ago

Biocardia Phase 3 CardiAMP-HF Trial of Novel Cardiac Cell Therapy for Ischemic Heart Failure Shows Increased Survival, Decreased Cardiac Events, and Improved Quality of Life at Two Years

BioCardia Full Year 2024 Earnings: EPS Beats Expectations, Revenues Lag

Simply Wall St.

7 months ago

BioCardia Full Year 2024 Earnings: EPS Beats Expectations, Revenues Lag

BioCardia Reports 2024 Business Highlights and Financial Results

GlobeNewswire

7 months ago

BioCardia Reports 2024 Business Highlights and Financial Results

What To Expect From BioCardia Inc (BCDA) Q4 2024 Earnings

GuruFocus.com

7 months ago

What To Expect From BioCardia Inc (BCDA) Q4 2024 Earnings

BioCardia to Host 2024 Financial Results and Corporate Update Conference Call on March 31, 2025

GlobeNewswire

7 months ago

BioCardia to Host 2024 Financial Results and Corporate Update Conference Call on March 31, 2025

Argus Research

7 months ago

Daily – Vickers Top Insider Picks for 03/21/2025

MT Newswires

7 months ago

BioCardia Gets Patent in Japan for Helix Biotherapeutic Delivery System

BioCardia Announces Japanese Patent for Helix™ Biotherapeutic Delivery System

GlobeNewswire

7 months ago

BioCardia Announces Japanese Patent for Helix™ Biotherapeutic Delivery System

BioCardia Announces Primary Outcome Measures Data Freeze in CardiAMP Heart Failure Trial for Presentation at the American College of Cardiology 2025 Scientific Sessions

GlobeNewswire

8 months ago

BioCardia Announces Primary Outcome Measures Data Freeze in CardiAMP Heart Failure Trial for Presentation at the American College of Cardiology 2025 Scientific Sessions

BioCardia Reports Completion of Low Dose Cohort Enrollment for CardiALLO Phase I/II Clinical Trial of BCDA-03 Allogeneic Mesenchymal Stem Cells to Treat Ischemic Heart Failure of Reduced Ejection Fraction (HFrEF)

GlobeNewswire

8 months ago

BioCardia Reports Completion of Low Dose Cohort Enrollment for CardiALLO Phase I/II Clinical Trial of BCDA-03 Allogeneic Mesenchymal Stem Cells to Treat Ischemic Heart Failure of Reduced Ejection Fraction (HFrEF)

BioCardia upgraded to Buy from Neutral at Alliance Global Partners

TipRanks

9 months ago

BioCardia upgraded to Buy from Neutral at Alliance Global Partners

BioCardia Announces Late Breaking Clinical Trial Presentation on CardiAMP Heart Failure Trial at the American College of Cardiology 2025 Scientific Sessions

GlobeNewswire

9 months ago

BioCardia Announces Late Breaking Clinical Trial Presentation on CardiAMP Heart Failure Trial at the American College of Cardiology 2025 Scientific Sessions

BioCardia Announces Commercial Availability of Morph® DNA™ Steerable Introducer Product Family

GlobeNewswire

10 months ago

BioCardia Announces Commercial Availability of Morph® DNA™ Steerable Introducer Product Family

BioCardia Announces Positive Consultation with Japan PMDA on CardiAMP Cell Therapy for Ischemic Heart Failure

GlobeNewswire

10 months ago

BioCardia Announces Positive Consultation with Japan PMDA on CardiAMP Cell Therapy for Ischemic Heart Failure

BioCardia Third Quarter 2024 Earnings: US$0.61 loss per share (vs US$1.79 loss in 3Q 2023)

Simply Wall St.

a year ago

BioCardia Third Quarter 2024 Earnings: US$0.61 loss per share (vs US$1.79 loss in 3Q 2023)

BioCardia Inc (BCDA) Q3 2024 Earnings Call Highlights: Breakthroughs and Challenges in Cardiac ...

GuruFocus.com

a year ago

BioCardia Inc (BCDA) Q3 2024 Earnings Call Highlights: Breakthroughs and Challenges in Cardiac ...

BioCardia Reports Third Quarter 2024 Business Highlights and Financial Results

GlobeNewswire

a year ago

BioCardia Reports Third Quarter 2024 Business Highlights and Financial Results

BioCardia to Host Q3 2024 Corporate Update and Financial Results Conference Call on November 13, 2024

GlobeNewswire

a year ago

BioCardia to Host Q3 2024 Corporate Update and Financial Results Conference Call on November 13, 2024

BioCardia Completes Phase III Randomized Double-Blind Controlled Trial of Autologous Cell Therapy for Ischemic Heart Failure

GlobeNewswire

a year ago

BioCardia Completes Phase III Randomized Double-Blind Controlled Trial of Autologous Cell Therapy for Ischemic Heart Failure

BioCardia Inc (BCDA) Q2 2024 Earnings Call Highlights: Strategic Advances Amid Financial Challenges

GuruFocus.com

a year ago

BioCardia Inc (BCDA) Q2 2024 Earnings Call Highlights: Strategic Advances Amid Financial Challenges

MT Newswires

a year ago

BioCardia Regains Compliance with Nasdaq Listing Rules for Minimum Equity Levels

BioCardia Regains Full Compliance with Nasdaq Listing Requirements

GlobeNewswire

a year ago

BioCardia Regains Full Compliance with Nasdaq Listing Requirements

BioCardia Announces Closing of Upsized $7.2 Million Public Offering Priced At-The-Market Under Nasdaq Rules

GlobeNewswire

a year ago

BioCardia Announces Closing of Upsized $7.2 Million Public Offering Priced At-The-Market Under Nasdaq Rules

MT Newswires

a year ago

BioCardia Prices $7.2 Million Public Offering

BioCardia Announces Pricing of Upsized $7.2 Million Public Offering Priced At-The-Market Under Nasdaq Rules

GlobeNewswire

a year ago

BioCardia Announces Pricing of Upsized $7.2 Million Public Offering Priced At-The-Market Under Nasdaq Rules

MT Newswires

a year ago

Top Midday Gainers

MT Newswires

a year ago

Sector Update: Health Care Stocks Advance Premarket Thursday

BioCardia Announces FDA Market Clearance of Morph® DNA™ Steerable Introducer Product Family

GlobeNewswire

a year ago

BioCardia Announces FDA Market Clearance of Morph® DNA™ Steerable Introducer Product Family

MT Newswires

a year ago

Top Premarket Gainers

MT Newswires

a year ago

BioCardia Says FDA Cleared Morph DNA Steerable Introducer; Shares Soar Pre-Bell

FDA Approves CardiAMP® Heart Failure II Protocol Amendment to Use Proprietary Cell Population Analysis Screening to Define Treatment

GlobeNewswire

a year ago

FDA Approves CardiAMP® Heart Failure II Protocol Amendment to Use Proprietary Cell Population Analysis Screening to Define Treatment

BioCardia Reports Second Quarter 2024 Business Highlights and Financial Results

GlobeNewswire

a year ago

BioCardia Reports Second Quarter 2024 Business Highlights and Financial Results

BioCardia to Host Q2 2024 Corporate Update and Financial Results Conference Call on August 13, 2024

GlobeNewswire

a year ago

BioCardia to Host Q2 2024 Corporate Update and Financial Results Conference Call on August 13, 2024

BioCardia Submits for FDA Approval of Morph® DNA™ Steerable Introducer Product Family

GlobeNewswire

a year ago

BioCardia Submits for FDA Approval of Morph® DNA™ Steerable Introducer Product Family

Patient Enrollment Commenced in Pivotal Phase 3 Trial of CardiAMP Cell Therapy for the Treatment of Ischemic Heart Failure

GlobeNewswire

a year ago

Patient Enrollment Commenced in Pivotal Phase 3 Trial of CardiAMP Cell Therapy for the Treatment of Ischemic Heart Failure

MT Newswires

a year ago

BioCardia Receives Patent for Morph DNA Transseptal Delivery

BioCardia Announces United States Patent Issuance on Morph DNA Multi-Directional Steerable Catheter Transseptal Application

GlobeNewswire

a year ago

BioCardia Announces United States Patent Issuance on Morph DNA Multi-Directional Steerable Catheter Transseptal Application

Share on Social Networks: